Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm [4]

Clinical Endocrinology

Volumn 65, Issue 4, 2006, Pages 552-553

  Syro, Luis V ^a   Uribe, Humberto ^b   Penagos, Luis C ^c   Ortiz, Leon D ^d   Fadul, Camilo E ^e   Horvath, Eva ^f   Kovacs, Kalman ^f  

^a HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^b Clinica SOMA   (Colombia)

^c Clinica Medellin   (Colombia)

^d Section of Neuro oncology   (Colombia)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN; TEMOZOLOMIDE;

ADULT; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL PROLIFERATION; CHRONOTHERAPY; CRANIOTOMY; DRUG EFFECT; DRUG TREATMENT FAILURE; ELECTRON MICROSCOPY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IMMUNOHISTOCHEMISTRY; LETTER; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS; DACARBAZINE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 33748799412     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02653.x     Document Type: Letter

References (6)

1. Newlands, E.S., Stevens, M.F.G., Wedge, S.R., Wheelhouse, R.T. & Brock, C. (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Review, 23, 35-61.
2. Newlands, E.S., O'Reilly, S.M., Glaser, M.G., Bower, M., Evans, H., Brock, C., Brampton, M.H., Colquhoun, I., Lewis, P., Rice-Edwards, J.M., Illingworth, R.D. & Richards, P.G. (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer, 32A, 2236-2241.
3. Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S. & Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology, 17, 2762-2771.
4. Stupp, R., Gander, M., Leyvraz, S. & Newlands, E. (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncology, 2, 552-560.
5. Fadul, C.E., Kominsky, A.L., Meyer, L.P., Kingman, L.S., Kinlaw, W.B., Rhodes, C.H., Eskey, C.J., Pepin, S.E. & Simmons, N.E. (2004) Pituitary carcinomas respond to temozolomide. Neuro-Oncology, 6, 374.
6. Zhu, Y., Shahinian, H., Hakimian, B., Bonert, V., Lim, S. & Heaney, A. (2004) Temodar: novel treatment for pituitary carcinoma. US Endocrine Society, 43-5, 138.